QPPV.COM KNOWLEDGE ASSESSMENT

Zilganersen: From GFAP Antisense Discovery to the First Approved Treatment for Alexander Disease

Test your understanding of the concepts covered by Zilganersen: From GFAP Antisense Discovery to the First Approved Treatment for Alexander Disease.

Question 1 of 10Pass mark: 80%

Question 1 of 10 What is the most important pharmacovigilance governance implication of the ex-U.S. licensing arrangement between Ionis and Recordati?

Responsibilities and operational arrangements for safety-data exchange, case reconciliation, signal assessment and regulatory activities need to be clearly established across the relevant parties. The licensing agreement automatically transfers all pharmacovigilance obligations to Recordati in every jurisdiction. The agreement makes safety information collected in one region irrelevant to another region. The commercial arrangement removes the need for local legal assessment of reporting responsibilities.

Question 2 of 10 Why is the randomized period generally more informative for comparative efficacy than the subsequent open-label period?

The randomized period retains a concurrent control comparison, whereas participants receiving active treatment in the open-label period do not provide the same controlled comparison. Open-label observations cannot provide any useful safety information. The randomized period includes only biomarker outcomes, while the open-label period includes all clinical outcomes. The open-label period automatically eliminates bias because everyone knows which treatment is given.

Question 3 of 10 Which statement best distinguishes regulatory designations such as orphan, Fast Track or Breakthrough Therapy from evidence of clinical benefit?

These designations support or facilitate development and review but are not themselves proof of efficacy or safety. Any one of these designations establishes clinical efficacy. Orphan designation confirms that all postmarketing risks are characterized. Priority Review means the medicine has received authorization in every relevant jurisdiction.

Question 4 of 10 What is the most accurate regulatory interpretation of the September 2026 U.S. approval for an EU pharmacovigilance professional?

It establishes a U.S. authorization but does not itself create an EU marketing authorisation or determine future EU product information and obligations. It automatically authorizes marketing throughout the European Union. It makes the U.S. label the legally applicable EU reference safety information. It removes the need for a future EU risk-management plan if an EU application is submitted.

Question 5 of 10 Why should safety systems link ION373, zilganersen and the marketed product name where applicable?

Consistent identification supports retrieval and reconciliation of safety information as the product moves from clinical development to commercial use. Different names indicate that the products have different active substances and should never be linked. Historical trial cases are irrelevant after a product receives a marketing name. Using multiple names eliminates the need to assess duplicate reports.

Question 6 of 10 A patient tests positive for anti-drug antibodies but has no change in safety, efficacy or pharmacokinetics. Which conclusion is best supported?

Antibody detection alone is not an adverse event and does not establish a clinically meaningful effect; the relationship requires further assessment. The result proves that the patient has immune-mediated meningitis. The result proves that treatment has lost efficacy. The result requires permanent treatment discontinuation in every case.

Question 7 of 10 Why is long-term follow-up particularly important for zilganersen?

Repeated treatment over years raises questions about durability, cumulative or delayed safety findings, immunogenicity and differences across phenotypes that a short controlled period may not resolve. Long-term follow-up is needed only to repeat the initial randomized efficacy analysis. The existence of a long-term extension proves that delayed adverse effects will occur. Once a biomarker changes, further clinical follow-up has no value.

Question 8 of 10 Why should a pharmacovigilance assessment avoid assuming that every adverse event following zilganersen is caused by GFAP suppression?

The product has both target-related considerations and risks arising from repeated intrathecal administration, and temporal association alone does not establish causality. GFAP is expressed only in diseased astrocytes, so target suppression cannot affect normal biology. All events occurring after lumbar puncture are necessarily procedure-related rather than drug-related. Antisense medicines cannot produce adverse effects through their molecular target.

Question 9 of 10 A report describes lower plasma GFAP after treatment but no documented functional change. What is the most appropriate interpretation?

The result supports biological activity or target engagement but does not, by itself, establish clinical benefit for that patient. The result proves that the patient's motor function has improved, even if no functional assessment was performed. The result establishes that the patient will respond clinically to continued treatment. The result is evidence of an adverse reaction because GFAP is a normal protein.

Question 10 of 10 How should the absence of study data in patients aged 65 years and older or certain patients with organ impairment be interpreted?

As an evidence gap that warrants careful interpretation and surveillance, not as proof of either safety or harm in those groups. As proof that treatment is unsafe in every such patient. As proof that risk is identical to that in the studied population. As evidence that adverse-event reporting is unnecessary for these patients.

Zilganersen: From GFAP Antisense Discovery to the First Approved Treatment for Alexander Disease

Cookie Settings